✦ LIBER ✦

Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study

✍ Scribed by A. Gabizon; T. Peretz; A. Sulkes; S. Amselem; R. Ben-Yosef; N. Ben-Baruch; R. Catane; S. Biran; Y. Barenholz

Book ID: 118154808
Publisher: Elsevier Science
Year: 1989
Weight: 926 KB
Volume: 25
Category: Article
ISSN: 0277-5379
DOI: 10.1016/0277-5379(89)90350-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I/II study of intraperitoneally

A phase I/II study of intraperitoneally administered doxorubicin entrapped in cardiolipin liposomes in patients with ovarian cancer

✍ Delgado, Gregorio; Potkul, Ronald K.; Treat, Joseph A.; Lewandowski, George S.; 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 890 KB

Phase I Study of Nonpegylated Liposomal

Phase I Study of Nonpegylated Liposomal Doxorubicin plus Trastuzumab in Patients with HER2-Positive Breast Cancer

✍ Maria Theodoulou; Gerald Batist; Susana Campos; Eric Winer; Lauri Welles; Cliffo 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 127 KB

Phase II Study of Liposomal Doxorubicin

Phase II Study of Liposomal Doxorubicin in Advanced Gynecologic Cancers

✍ Valerie P. Israel; Augustin A. Garcia; Linda Roman; Laila Muderspach; Alexander 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 47 KB

A Phase I Study of Pegylated Liposomal D

A Phase I Study of Pegylated Liposomal Doxorubicin and Irinotecan in Patients with Solid Tumors

✍ Morgensztern, Daniel; Baggstrom, Maria Q.; Pillot, Giancarlo; Tan, Benjamin; Fra 📂 Article 📅 2009 🏛 S. Karger AG 🌐 English ⚖ 133 KB

Phase I study of pegylated liposomal dox

Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies

✍ Paula M. Fracasso; Kristie A. Blum; Benjamin R. Tan; Carole L. Fears; Nancy L. B 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 2 views

## Abstract ## BACKGROUND Pegylated liposomal doxorubicin (PEG‐LD) and gemcitabine have single‐agent activity in breast and ovarian carcinoma patients. We conducted a Phase I trial to evaluate the maximum tolerated dose (MTD) and toxicities of this combination in patients with advanced malignancie

A phase I study of pegylated liposomal d

A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies

✍ Wang-Gillam, Andrea; Thakkar, Nilay; Lockhart, A. Craig; Williams, Kerry; Baggst 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 282 KB